The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease
Open accessAbstract
BACKGROUND: Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic hematopoietic stem-cell transplantation (HSCT). The chemokine receptor CCR5 appears to play a role in alloreactivity. We tested whether CCR5 blockade would be safe and limit GVHD in humans. METHODS: We tested the in vitro effect of the CCR5 antagonist maraviroc on lymphocyte function and chemotaxis. We then enrolled 38 high-risk patients in a single-group phase 1 and 2 study of reduced-intensity allogeneic HSCT that combined maraviroc with standard GVHD prophylaxis. RESULTS: Maraviroc inhibited CCR5 internalization and lymphocyte chemotaxis in vitro without impairing T-cell function or formation of hematopoietic-cell colonies. In 35 patients who could be evaluated, the cumulative incidence rate (±SE) of grade II to IV acute GVHD was low at 14.7±6.2% on day 100 and 23.6±7.4% on day 180. Acute liver and gut GVHD were not observed before day 100 and remained uncommon before day 180, resulting in a low cumulative incidence of grade III or IV GVHD on day 180 (5.9±4.1%). The 1-year rate of death that was not preceded by disease relapse was 11.7±5.6% without excessive rates of relapse or infection. Serum from patients receiving maraviroc prevented CCR5 internalization by CCL5 and blocked T-cell chemotaxis in vitro, providing evidence of antichemotactic activity. CONCLUSIONS: In this study, inhibition of lymphocyte trafficking was a specific and potentially effective new strategy to prevent visceral acute GVHD. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00948753.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
Springer, T. A. (1994) · Cell · doi:10.1016/0092-8674(94)90337-9 · Cited by 6,929
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G.-S., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.12.001 · Cited by 5,459
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Zlotnik, A., & Yoshie, O. (2000) · Immunity · doi:10.1016/s1074-7613(00)80165-x · Cited by 3,859
Filipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., et al. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.09.004 · Cited by 3,556
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) · Blood · doi:10.1182/blood.v91.3.756 · Cited by 2,071
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,389
The ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry
SUTHERLAND, D. R., ANDERSON, L., KEENEY, M., NAYAR, R., & CHIN-YEE, I. (1996) · Journal of Hematotherapy · doi:10.1089/scd.1.1996.5.213 · Cited by 1,275
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationDorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
CCR5 is characteristic of Th1 lymphocytes
Loetscher, P., Uguccioni, M., Bordoli, L., Baggiolini, M., Moser, B., Chizzolini, C., & Dayer, J.-M. (1998) · Nature · doi:10.1038/34814 · Cited by 866
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803152 · Cited by 752
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Jagasia, M., Arora, M., Flowers, M. E. D., Chao, N. J., McCarthy, P. L., Cutler, C. S., Urbano-Ispizua, A., Pavletic, S. Z., Haagenson, M. D., Zhang, M.-J., et al. (2012) · Blood · doi:10.1182/blood-2011-06-364265 · Cited by 707
Flowers, M. E. D., Inamoto, Y., Carpenter, P. A., Lee, S. J., Kiem, H.-P., Petersdorf, E. W., Pereira, S. E., Nash, R. A., Mielcarek, M., Fero, M. L., et al. (2011) · Blood · doi:10.1182/blood-2010-08-302109 · Cited by 690
Nash, R. A., Antin, J. H., Karanes, C., Fay, J. W., Avalos, B. R., Yeager, A. M., Przepiorka, D., Davies, S. M., Petersen, F. B., Bartels, P., et al. (2000) · PubMed · Cited by 589
Giralt, S., Thall, P. F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Donato, M., Bruton, J., Cohen, A., et al. (2001) · Blood · doi:10.1182/blood.v97.3.631 · Cited by 568
Mielcarek, M., Martin, P. J., Leisenring, W., Flowers, M. E. D., Maloney, D. G., Sandmaier, B. M., Maris, M. B., & Storb, R. (2003) · Blood · doi:10.1182/blood-2002-08-2628 · Cited by 562
Giralt, S., Thall, P. F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Donato, M., Bruton, J., Cohen, A., et al. (2001) · Blood · doi:10.1182/blood.v97.3.631.h8000631_631_637 · Cited by 514
Fätkenheuer, G., Pozniak, A. L., Johnson, M. A., Plettenberg, A., Staszewski, S., Hoepelman, A. I. M., Saag, M. S., Goebel, F. D., Rockstroh, J. K., Dezube, B. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1319 · Cited by 495
Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I. M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803154 · Cited by 364
Pathophysiologic mechanisms of acute graft-vs.-host disease
Ferrara, J. L. M., Levy, R., & Chao, N. J. (1999) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(99)70011-x · Cited by 340
Donor APCs are required for maximal GVHD but not for GVL
Matte, C. C., Liu, J., Cormier, J., Anderson, B. E., Athanasiadis, I., Jain, D., McNiff, J., & Shlomchik, W. D. (2004) · Nature Medicine · doi:10.1038/nm1089 · Cited by 318
Carlson, M. J., West, M. L., Coghill, J. M., Panoskaltsis-Mortari, A., Blazar, B. R., & Serody, J. S. (2009) · Blood · doi:10.1182/blood-2008-06-162420 · Cited by 302
Murai, M., Yoneyama, H., Harada, A., Yi, Z., Vestergaard, C., Guo, B., Suzuki, K., Asakura, H., & Matsushima, K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6642 · Cited by 301
Alyea, E. P., Kim, H. T., Ho, V., Cutler, C., Gribben, J., DeAngelo, D. J., Lee, S. J., Windawi, S., Ritz, J., Stone, R. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1947 · Cited by 300
CC chemokine receptor 5 and renal-transplant survival
Fischereder, M., Luckow, B., Hocher, B., Wüthrich, R. P., Rothenpieler, U., Schneeberger, H., Panzer, U., Stahl, R. A., Hauser, I. A., Budde, K., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04898-4 · Cited by 292
Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction
Murai, M., Yoneyama, H., Ezaki, T., Suematsu, M., Terashima, Y., Harada, A., Hamada, H., Asakura, H., Ishikawa, H., & Matsushima, K. (2003) · Nature Immunology · doi:10.1038/ni879 · Cited by 290
Yi, T., Chen, Y., Wang, L., Du, G., Huang, D., Zhao, D., Johnston, H., Young, J., Todorov, I., Umetsu, D. T., et al. (2009) · Blood · doi:10.1182/blood-2009-05-219402 · Cited by 280
Ringdén, O., Labopin, M., Ehninger, G., Niederwieser, D., Olsson, R., Basara, N., Finke, J., Schwerdtfeger, R., Eder, M., Bunjes, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9692 · Cited by 271
Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets
Nikolic, B., Lee, S., Bronson, R. T., Grusby, M. J., & Sykes, M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7894 · Cited by 228
Alousi, A. M., Weisdorf, D. J., Logan, B. R., Bolaños-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B., et al. (2009) · Blood · doi:10.1182/blood-2009-03-212290 · Cited by 222
Self-citationZhang, Y., Louboutin, J.-P., Zhu, J., Rivera, A. J., & Emerson, S. G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14989 · Cited by 188
Self-citationChoi, S. W., Hildebrandt, G. C., Olkiewicz, K. M., Hanauer, D. A., Chaudhary, M. N., Silva, I. A., Rogers, C. E., Deurloo, D. T., Fisher, J. M., Liu, C., et al. (2007) · Blood · doi:10.1182/blood-2007-05-087403 · Cited by 81
Welniak, L. A., Kuprash, D. V., Tumanov, A. V., Panoskaltsis‐Mortari, A., Blazar, B. R., Sun, K., Nedospasov, S. A., & Murphy, W. J. (2005) · Blood · doi:10.1182/blood-2004-11-4565 · Cited by 48
Cited by
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1609337 · Cited by 1,296
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Self-citationHalama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 378
Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323
Self-citation
Metadata
- Authors
- Reshef, R., Luger, S. M., Hexner, E. O., Loren, A. W., Frey, N. V., Nasta, S. D., Goldstein, S. C., Stadtmauer, E. A., Smith, J., Bailey, S., Mick, R., Heitjan, D. F., Emerson, S. G., Hoxie, J. A., Vonderheide, R. H., & Porter, D. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-12
- Volume
- 367
- Issue
- 2
- Pages
- 135-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2006427551
- Cited by
- 254
- References
- 36
- FWCI
- 19.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.